Xstrahl is a leading designer and manufacturer of superficial orthovoltage X-ray systems used in the treatment of cancers and dermatological disorders, as well as a pioneer in the development of advanced X–ray systems for pre-clinical radiation biology research.

The company is headquartered in Britain and has facilities in the US.  The majority of its production is exported to over 25 countries.  Its customers are mainly hospitals and laboratories.

Risk Capital Partners invested in 2018, to support the existing management team, led by the CEO Adrian Treverton.

Why we invested:

  • Global market leader in both its niche medical, and pre-clinical research markets
  • Global customer base, spanning over 25 countries
  • Highly creative team, with a track record for driving leading product developments
  • Focused on treating the growing global cancer epidemic
  • Opportunity for strategic acquisitions in medical devices and equipment

“I am excited by the opportunity to lead the buyout of Xstrahl, supported by Luke Johnson and Risk Capital Partners.   Their entrepreneurial approach resonated with our management team.  Our intention is to continue to grow Xstrahl, through innovation and close collaboration with our customers.”
Adrian Treverton